Concepedia

N. Vachharajani

NV

Statistics

Publications

5

Citations

791

H-Index

5

Active since

2001

Affiliations

Bristol-Myers Squibb (United States)(Current)

N. Vachharajani is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, pharmacokinetics, and clinical pharmacology.

Publications per year

2001–2011

5

Publications

5

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

Bernard J. Komoroski, N. Vachharajani, L Li et al. · Clinical Pharmacology & Therapeutics · 2009 · 392 citations

, , +17

Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

Bernard J. Komoroski, N. Vachharajani, David W. Boulton et al. · Clinical Pharmacology & Therapeutics · 2009 · 346 citations · Full text

, , +16

Saxagliptin, a potent, selective inhibitor of DPP‐4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects

Chirag G. Patel, David M. Kornhauser, N. Vachharajani et al. · Diabetes Obesity and Metabolism · 2011 · 20 citations

, , +17

A Pharmacokinetic Interaction Study Between Butorphanol and Sumatriptan Nasal Sprays in Healthy Subjects: Importance of the Timing of Butorphanol Administration

N. Vachharajani, W. C. Shyu, PS Nichola et al. · Cephalalgia · 2002 · 18 citations

, , +15

The Pharmacokinetics and Pharmacodynamics of Irbesartan in Heart Failure

John B. Kostis, N. Vachharajani, Ophelia W. Hadjilambris et al. · The Journal of Clinical Pharmacology · 2001 · 15 citations

, , +17

1–5 of 5